Selective secreted phospholipase A2
) inhibitor (IC50
= 50 - 750 nM for a range of sPLA2
isoforms). Has no effect on cytosolic PLA2
or COX-1 and COX-2 activity. Attenuates sPLA2
-induced thromboxane formation in bronchoalveolar lavage (BAL) cells. Also suppresses sPLA2
-induced contractions of lung pleural strips ex vivo
. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI.
Snyder et al.
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2.
Oslund et al.